T regulatory cells lacking CD25 are increased in MS during relapse

Autoimmunity

Volumn 43, Issue 8, 2010, Pages 590-597

  Fransson, Moa ^a   Burman, Joachim ^b   Lindqvist, Camilla ^a   Atterby, Christina ^a   Fagius, Jan ^b   Loskog, Angelica ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CD25; FoxP3; MS; T cells; T regulatory cells

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; REGULATORY T LYMPHOCYTE; RELAPSE;

ADULT; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LINEAR MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; T-LYMPHOCYTES, REGULATORY;

EID: 78149424440     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916930903541190     Document Type: Article

References (30)

1. Costantino CM, Baecher-Allan C, Hafler DA. Multiple sclerosis and regulatory T cells. J Clin Immunol 2008;28(6):697-706.
2. Toubi E. The role of CD4+CD25+T regulatory cells in autoimmune diseases. Clin Rev Allergy Immunol 2008;34(3): 338-344.
3. Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, Bowcock AM. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregula-tion syndrome. J Clin Invest 2000;106(12):R75-R81.
4. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Bricarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME. X-linked neonatal diabetes mellitus, entero-pathy and endocrinopathy syndrome is the human equivalent ofmouse scurfy. Nat Genet 2001;27(1):18-20.
5. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations ofFOXP3. Nat Genet 2001;27(1):20-21.
6. Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Maeda M, Onodera M, Uchiyama T, Fujii S, Sakaguchi S. Crucial role of FOXP3 in the development and function of human CD25+ CD4+ regulatoryT cells. Int Immunol 2004; 16(11):1643-1656.
7. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008;112(6): 2340-2352.
8. Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 2008;4(7):384-398.
9. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simeone D, Redman B, Welling TH, Chang A, Zou W. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009;69(9): 3995-4000.
10. Banham AH. Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. Trends Immunol 2006;27(12):541-544.
11. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203(7):1693-1700.
12. Bonelli M, Savitskaya A, Steiner CW, Rath E, Smolen JS, Scheinecker C. Phenotypic and functional analysis of CD4+ CD25\Foxp3+T cells in patients with systemic lupus erythematosus. JImmunol 2009;182(3):1689-1695.
13. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13(3):227-231.
14. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50(1): 121-127.
15. Wang HY, Wang RF, Regulatory T cells and cancer. Curr Opin Immunol 2007;19(2):217-223.
16. Venken K, Hellings N, Hensen K, Rummens JL, Medaer R, D'Hooghe MB, Dubois B, Raus J, Stinissen P. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+ CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 2006; 83(8):1432-1446.
17. Huan J, Culbertson N, Spencer L, Bartholomew R, Burrows GG, Chou YK, Bourdette D, Ziegler SF, Offner H, Vandenbark AA. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005;81(1):45-52.
18. Venken K, Hellings N, Broekmans T, Hensen K, Rummens JL, Stinissen P. Natural naive CD4+ CD25 + CD127 low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: Recovery of memory Treg homeostasis during disease progression. JImmunol 2008;180(9):6411-6420.
19. Fransson ME, Liljenfeldt LS, Fagius J, Totterman TH, Loskog AS. The T-cell pool is anergized in patients with multiple sclerosis in remission. Immunology 2009;126(1):92-101.
20. Stephens LA, Mason D. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25\subpopulations. J Immunol 2000; 165(6):3105-3110.
21. Hori S, Nomura T, Sakaguchi S. Control ofregulatory T cell development by the transcription factor Foxp3. Science 2003;299(5609):1057-1061.
22. Nishimura E, Sakihama T, Setoguchi R, Tanaka K, Sakaguchi S. Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3 + CD25 + CD4+ regulatory T cells. Int Immunol 2004;16(8):1189-1201.
23. Matsui M, Araya S, Wang HY, Matsushima K, Saida T Differences in systemic and central nervous system cellular immunity relevant to relapsing-remitting multiple sclerosis. J Neurol 2005;252(8):908-915.
24. Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Wurfel J, Ohayon J, Waldmann TA, McFarland HF, Martin R. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004;101(23):8705-8708.
25. Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S, Lopez-Diaz de Cerio A, Palacios R, Sepulcre J, Moreno B, Gonzalez Z, Fernandez-Diez B, Melero I, Bendandi M, Villoslada P. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol 2008;38(2):576-586.
26. Venken K, Hellings N, Thewissen M, Somers V, Hensen K, Rummens JL, Medaer R, Hupperts R, Stinissen P. Compromised CD4+ CD25(high) regulatory T-cell func-tion in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 2008;123(1):79-89.
27. O'Connor RA, Anderton SM. Foxp3+ regulatory T cells in the control of experimental CNS autoimmune disease. J Neuroimmunol 2008;193(1-2):1-11.
28. Markowitz CE. Interferon-beta: Mechanism of action and dosing issues. Neurology 2007;68(24 Suppl 4):S8-S11.
29. Penton-Rol G, Cervantes-Llanos M, Cabrera-Gomez JA, Alonso-Ramirez R, Valenzuela-Silva C, Rodriguez-Lara R, Montero-Casimiro E, Bello-Rivero I, Lopez-Saura P. Treat-ment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients. Int Immunopharmacol 2008;8(6):881-886.
30. Martin-Saavedra FM, Gonzalez-Garcia C, Bravo B, Ballester S. Beta interferon restricts the inflammatory potential of CD4+ cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol 2008;45(15):4008-4019.